 Mesoblast Limited NASDAQ: MESO shares dived on Tuesday as the FDA raised more questions around its flagship drug candidate, and its annual loss widened. What Happened: In the June quarter, Mesoblast met FDA on potential regulatory approval of remestemcel-L, used to treat acute graft versus host disease SR-aGVHD in children and treat acute respiratory distress syndrome ARDS in adults with COVID-19. 